Generic Medicine Info
May be taken with or without food. FC tab/tab: May be divided along the score line.
Gastroretentive tab: Should be taken with food. Take with evening meal. Swallow whole, do not split/crush/chew.
Special Precautions
Patient with mixed seizures (including absences), compromised respiratory function, respiratory disease, neurological disease, history of substance abuse, myasthenia gravis, poor general health (e.g. low body weight, organ transplant recipient). Avoid abrupt withdrawal; reduce dose gradually over at least 7 days (regardless of indication). Patient concomitantly receiving CNS depressants (e.g. opioids). Various preparations are available that are not interchangeable; refer to specific product guideline for detailed information . Renal impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Assess for history of substance abuse prior to initiation of treatment. Monitor renal function periodically. Monitor for symptoms of respiratory depression and sedation in patients with respiratory disease. Observe for signs and symptoms of suicidal ideation and behaviour, drug abuse and dependence (e.g. drug-seeking behaviour, development of tolerance), mental alertness, hypersensitivity.
Adverse Reactions
Significant: Anaphylaxis, angioedema, suicidal ideation and behaviour, acute pancreatitis, onset of new types of seizures, increase in seizure frequency; dizziness, somnolence, confusion, mental impairment; drug abuse and dependence, withdrawal symptoms; neuropsychiatric reactions (e.g. emotional lability, thought disorder, hostility, hyperkinesia) in children. Blood and lymphatic system disorders: Leucopenia. Ear and labyrinth disorders: Otitis media, vertigo. Eye disorders: Visual disturbances (e.g. amblyopia, diplopia). Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, dry mouth or throat, flatulence, dyspepsia, constipation, dental abnormalities, gingivitis. General disorders and administration site conditions: Fever, fatigue, asthenia, pain, peripheral oedema, abnormal gait, flu syndrome, fractures. Infections and infestations: Viral infection. Injury, poisoning and procedural complications: Accidental injury. Investigations: Decreased WBC, weight gain. Metabolism and nutrition disorders: Anorexia, increased appetite. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia, twitching, back pain. Nervous system disorders: Headache, ataxia, amnesia, dysarthria, abnormal sensation (e.g. paraesthesia), tremor, abnormal coordination, nystagmus, abnormal reflexes (e.g. increased, decreased, or absent), abnormal thinking. Psychiatric disorders: Anxiety, depression, insomnia, nervousness. Renal and urinary disorders: UTI. Reproductive system and breast disorders: Impotence. Respiratory, thoracic and mediastinal disorders: Pneumonia, respiratory tract infection, dyspnoea, bronchitis, pharyngitis, cough, rhinitis. Skin and subcutaneous tissue disorders: Rash, pruritus, acne, purpura, abrasion. Vascular disorders: Hypertension, vasodilatation.
Potentially Fatal: Drug reaction with eosinophilia and systemic symptoms (DRESS)/multiorgan hypersensitivity; severe respiratory depression.
Drug Interactions
Reduced bioavailability with antacids containing Al and Mg.
CIMS Class
Anticonvulsants / Drugs For Neuropathic Pain
ATC Classification
N02BF01 - gabapentin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.
Disclaimer: This information is independently developed by CIMS based on gabapentin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in